See below to download the Meeting Impression

In this educational program chaired by David Fitchett and John Deanfield, which was held at the ESC Congress 2017 in Barcelona, Spain, Naveed Sattar, John Deanfield, and Stefan Anker discussed the role of diabetes treatment in the management of heart failure, as well as novel interventions targeted to improve cardiovascular (CV) outcomes. More specifically, the epidemiology and pathophysiology of patients with diabetes and at increased CV risk were summarized, and the role of the kidney in glucose homeostasis was explained. In addition, current interventions and the unmet need of impacting CV outcomes in diabetes were discussed, the effects of SGLT2 inhibition described, as well as future strategies in these multi-risk patients.

Educational information

The educational objectives of this symposium were to:

Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes

Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis

Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes

Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes

Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients

Faculty

• Prof. Naveed Sattar - Oxford, United Kingdom : SGLT2 inhibition in cardiology: What a cardiologist needs to know
• Prof. John Deanfield - University College London, United Kingdom : Management of CV Risk & T2DM: Implications of novel outcome trials
• Prof. Stefan Anker - Berlin, Germany : Heart failure & Diabetes: Time for a more unified approach

Disclosures

This satellite symposium was organised by the PACE Foundation and sponsored by an unrestricted educational grant of Boehringer Ingelheim/Lilly.

Download Meeting Impression View lectures - Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure